KINETIK: Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF
Study Details
Study Description
Brief Summary
Chronic kidney disease (CKD) is a critical comorbidity for patients living with HIV (PLWH), with an estimated prevalence between 2.4 and 17%, leading to end-stage renal disease 3 to 6 fold more than non-HIV population. However kidney transplantation for PLWH has become the first-line therapy for end-stage renal disease, with an enhanced survival benefit compared to remaining on dialysis.
Management of antiretroviral therapy (ART) in HIV-infected kidney transplant recipients (HIV-KTR) has historically been problematic because of the potential nephrotoxicity of some antiretroviral drugs and the interactions between calcineurin inhibitors, mTOR inhibitors, and ritonavir or cobicistat-boosted containing-ART. The use of tenofovir disoproxil fumarate (TDF), a widely recommended nucleotide analogue for the treatment of both HIV and HIV/hepatitis B virus (HBV) co-infection, is restricted in vulnerable kidney population as HIV-KTR due to its major potential toxicity consistent with tubular dysfunction and rarely with a progressive sustained decline in renal function. The optimal long-term ART regimen is not known in HIV-KTR, though it makes intuitive sense to avoid regimens containing TDF, given its potential nephrotoxicity. Nevertheless the potent virological efficacy of TDF both on HIV and HBV and its highest in-vitro barrier to resistance among the Nucleoside Reverse Transcriptase Inhibitors makes tenofovir use highly recommended or even essential in HIV/HBV co-infections.
Tenofovir alafenamide (TAF) and bictegravir (BIC) are 2 novel antiretroviral drug available in HIV treatment in combination with emtricitabine (F) (B/F/TAF):
- TAF is a novel prodrug of tenofovir that may offer improved renal safety over TDF. TAF is more stable in plasma and is metabolized intracellularly by cathepsin A, an enzyme that is highly expressed in lymphoid tissues. Therefore, TAF can achieve higher intracellular levels of the active moiety tenofovir diphosphate, with lower levels of circulating tenofovir when compared with TDF. This more targeted treatment could potentially result in fewer renal and bone complications despite the same clinical efficacy as TDF. TAF was approved for use in PLWH with mild-moderate CKD (eGFR: 30-69 mL/min).
The availability of TAF seems a potential addition to the antiretroviral armamentarium in HIV-KTR. * BIC is a novel second-generation integrase strand transfer inhibitor (INSTI) has a high in-vitro barrier to resistance and in-vitro activity against most INSTI-resistant variants and has low potential for clinically meaningful drug-drug interactions. BIC has been recently approved by the FDA, in coformulated B/F/TAF for the treatment of HIV-1 infection in antiretroviral naïve subjects and in those with suppressed viremia.
No data are available yet with TAF use in HIV-infected kidney transplant recipients as well as with BIC, especially about potential drug-to-drug interactions with immunosuppressive drugs such as calcineurin & mTOR inhibitors.
At last simplification to a single tablet regimen (STR) may offer a once-daily option for HIV-KTR who have multiple comorbidities, often requires complex regimens with a high pill burden.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: BIC/FTC/TAF Development phase 4: Biktarvy® |
Drug: Biktarvy Tab
Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.
|
Outcome Measures
Primary Outcome Measures
- Change in calcineurin & mTOR inhibitors' blood concentrations from baseline (BL) to W2 after switch to B/F/TAF [Week 2]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
• HIV-1 infected patients > 18 years
-
Antiretroviral treatment switch to BIC/FTC/TAF decided in standard care by physician
-
Kidney transplant recipient ≥ 3 months
-
Receiving calcineurin and/or mTOR inhibitors without change in doses ≥ 4 weeks
-
Plasma HIV RNA ≤ 50 cpml ≥ 6 months (1 blip permitted 200cp/ml)
-
eGFR (CKD-EPI) ≥ 30 ml/mn/1.73m2
-
Written consent
-
GSS to BIC/FTC/TAF ≥ 2
-
Active contraception in potential child-bearing women
Exclusion Criteria:
-
Allergy or intolerance to one of the following drug or to any of excipients: FTC, TDF, INSTI
-
Current ART containing TAF
-
HIV-2 or HIV-1/HIV-2 co-infection
-
Patients with severe hepatic impairment (Child-Pugh Class C)
-
Patient without health coverage
-
Pregnancy and breast-feeding
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
- LAMBERT ASSOUMOU/ UNITE 1136 INSERM
- Sebastien GALLIEN/Henri Mondor University Hospital- Infectiology Department
- THOMAS STEHL/ HENRI MONDOR HOSPITAL-Department of Nephrology
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IMEA 064